June 4th, 2014
Transcatheter Mitral Valve Programs: No Volume Data
Richard A. Lange, MD, MBA and L. David Hillis, MD
The Society for Cardiac Angiography and Interventions (SCAI), the American Association for Thoracic Surgery (AATS), the American College of Cardiology (ACC), and the Society of Thoracic Surgeons (STS) recently joined together to provide recommendations for institutions that are considering starting and/or maintaining a transcatheter mitral valve (MV) program. Unlike PCI, for which abundant data show a […]
May 19th, 2014
Case: A Young Pregnant Woman with Prior Valvular Disease and Increasing Dyspnea on Exertion
Reva Balakrishnan, MD, MPH and James Fang, MD
Reva Balakrishnan presents the case of a 22-year-old pregnant woman with a history of valvular disease who is experiencing an increase in dyspnea on exertion.
October 25th, 2013
FDA Approves Abbot’s MitraClip for Patients at Prohibitive Surgical Risk
Larry Husten, PHD
The FDA today approved Abbott’s catheter-based MitraClip device for patients with significant symptomatic degenerative MR who are at prohibitive risk for mitral valve surgery. The company said it would launch the device immediately in the United States. The device is the first percutaneous nonsurgical therapy approved for the treatment of mitral valve disease. Surgery remains the option […]
September 6th, 2013
Early Surgery vs. Watchful Waiting for Flail-Leaflet Mitral Regurgitation
Rakesh Mark Suri, MD, D.Phil., Maurice Enriquez-Sarano, MD and John Ryan, MD
Rakesh M. Suri and Maurice Enriquez-Sarano discuss their research group’s comparison of early mitral valve surgery with initial medical management among patients in the Mitral Regurgitation International Database.
March 21st, 2013
FDA Panel Gives Tepid Endorsement to Abbott’s MitraClip
Larry Husten, PHD
The FDA’s Circulatory System Devices advisory panel gave a tepid endorsement to Abbott Laboratories’ MitraClip device on Wednesday. The panel met to evaluate use of the novel device in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve surgery and in whom existing […]
June 27th, 2012
Panel: Early Surgery for Infective Endocarditis
Larry M. Baddour, MD, Sabet W Hashim, MD and John E Brush, MD
Will findings from this trial of early surgery for infective endocarditis change your practice?
June 11th, 2012
The Changing Face of Mitral Valve Surgery
John A. Dodson, MD
A new study of mortality and other trends among Medicare patients who undergo mitral valve surgery may influence whom you choose to refer for this type of procedure.
April 4th, 2011
MitraClip Compared with Surgery in EVEREST II
Larry Husten, PHD
The final results of the highly anticipated EVEREST (Endovascular Valve Edge-to-Repair Study) II were presented by Ted Feldman at the ACC Scientific Sessions in New Orleans and published simultaneously in the New England Journal of Medicine. Some 279 patients with moderately severe or severe mitral regurgitation (MR) were randomized on a 2:1 basis to either […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?